Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Trends that Matter for Biosimilars and Orphan Drugs

Posted by Matt Breese on Jan 8, 2016

Find me on:

A collection of engaging infographics from healthcare influencers to capture trends in emerging groups of pharmaceuticals, like biosimilars and orphan drugs.

U.S. retail pharmacies only distribute 5% of biologics on the market, according to the AfPA

biosimilar_substitution-afpa.jpg

Via Alliance for Patient Access

 

A staggering 95% of rare diseases have no approved pharmaceutical treatment in certain markets

ISR-infographic-orphan-drug-Feb2015-01.jpg

Via Orphan Drug 101

 

21 blockbuster biopharmaceutical products, representing $50 billion of annual market value, go off patent between 2009 and 2019


landscape_of_biosimilar_market-isr.jpg

Via ISR Reports

 

While orphan drugs treat rare diseases for less than 200,000 people in the U.S. according to ISR, the market represents a significant opportunity for biopharma manufacturers

ISR-drug-development.jpg

Check Out the Full Piece on Drug Development Trends Here

 

Follow us on Twitter to stay current with new biosimilar and orphan drug developments.

Follow MMIT on Twitter

Topics: Industry Trends, Market Access